The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- When Seconds Count: The Benefits of Drug Data Alerts
- From Theory to Reality: The Impact of Virtual Reality in Emergency Medical Training
- Protected: PEPID’s Impactful Collaboration with OKB Hope Foundation: Elevating Rural Healthcare
- The Robot Will See You Now… How AI & Robotics are Transforming the Healthcare Industry
- From Meal Prep to Calorie Tracking: Key Nutritional Habits Worth Embracing